Acute akinesia in Parkinson disease

Neurology

Volumn 64, Issue 7, 2005, Pages 1162-1169

  Onofrj, Marco ^a,b   Thomas, Astrid ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b Ospedale Civile di Pescara   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; APOMORPHINE; CARBIDOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; CREATINE KINASE; DANTROLENE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; MYOGLOBIN;

ADULT; AGED; AKINESIA; ARTICLE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HUMAN; HYPERTHERMIA; MAJOR CLINICAL STUDY; MALE; NEUROLEPTIC MALIGNANT SYNDROME; ON OFF PHENOMENON; PARKINSON DISEASE; PRIORITY JOURNAL; RATING SCALE; UNIFIED PARKINSONS DISEASE RATING SCALE;

EID: 16844383347     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000157058.17871.7B     Document Type: Article

References (33)

1. Tanner CM, Goetz CG, Klawans HL. Autonomic nervous system disorders. In: Koller WE, ed. Handbook of Parkinson's disease. New York: Marcel Dekker, 1987:161-163.
2. Danielczyk W. Twenty-five years of amantadine therapy in Parkinson's disease. J Neural Transm [Suppl] 1995;46:399-409.
3. Kornhuber J, Weller M, Riederer P. Glutamate receptor antagonists for neuroleptic malignant syndrome and akinetic hyperthermic parkinsonian crisis. J Neural Transm (Park Dis Dement Sect) 1993;6:63-72.
4. Lange KW, Kornhuber J, Riederer P. Dopamine/glutamate interactions in Parkinson's disease. Neurosci Behav Rev 1997;21:393-400.
5. Deutsche Gesellschaft fdur Neurologie: Leitlinien-Parkinson-Syndrome; 4,3,4,2 Akinetische Krise. www.dgn.org/168.0htlm 926.
6. Danielczyk W. Die Behandlung von akinetischen Krisen. Med Welt 1973;24:1278-1282.
7. Muschard G, Völler GW. Wirksamkeit von Amantadinsulfat als Infusionslösung bei der Behandlung des Parkinsons Sindroms. Med Welt 1973;24:183-184.
8. Oppel F, Klaes H. Die Amantadin-Infusionen in der akuten Behandlung der Morbus Parkinson. Klinikarzt 1981;10:559-565.
9. Gehlen W. Akinetic crises - a possible form of parkinsonism. Dtsch Med Wochenschr 1977;18:102.
10. Sundal E. Akinetic crises - a possible manifestation of Parkinson's disease. Tidsskr Nor Laegeforen 1978;28:98.
11. Bachli E, Albani C. Akinetic crisis in Parkinson's disease. Schweiz Med Wochenschr 1984;11:124.
12. Danielczyk W. Three crises in Parkinson disease. Fortschr Med 100 1982;1583-1585.
13. Friedman JH, Feinberg SS, Feldman RC. Neuroleptic malignant-like syndrome due to L-dopa withdrawal. Ann Neurol 1984;16:126.
14. Mizuno Y, Takubo H, Mizuta E, Kuno S. Malignant syndrome in Parkinson's disease: concept and review of the literature. Parkinsonism 2003;9:S3-S9.
15. Ueda M, Hamamoto M, Nagayama H, et al. Susceptibility to neuroleptic malignant syndrome in Parkinson's disease. Neurology 1999;52:777-781.
16. Takubo H, Harada T, Hashimoto T, et al. A collaborative study on the malignant syndrome in Parkinson's disease and related disorders. Parkinsonism 2003;9:S31-S41.
17. Pfeiffer RE, Sucha FL. "On/off"-induced lethal hyperthermia. Mov Disord 1989;4:338-341.
18. Stacy M, Factor S. Rapid treatment of "off" episodes. Will this change Parkinson disease therapy? Neurology 2004;62(suppl):S1-S2.
19. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinic-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
20. Fahn S, Elton R, members of UPDRS Development Committee. In: Fahn S, Marsden CD, Calne DB, Goldstein M, eds. Recent developments in Parkinson's disease, vol 2. Florham Park, NJ: Macmillan Health Care Information, 1987:153-164.
21. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967;17:427-442.
22. Nissinen E, Taskinen J. Simultaneous determination of carbidopa, levodopa and 3,4-dihydroxyphenylacetic acid using high performance liquid chromatography with electrochemical detection. J Chromatogr 1982;231:459-462.
23. Fabbrini G, Mouradian MM, Juncos JL, et al. Motor fluctuation in Parkinson's disease: central pathophysiological mechanisms, part I. Ann Neurol 1988;24:366-71.
24. Brindle GF. Anesthesia in the patient with parkinsonism. Primary Care 1977;4:513-528.
25. Severn AM. Parkinsonism and the anaesthetist. Br J Anaesth 1988;61:761-770.
26. Quinn NP. Classification of fluctuations in patients with Parkinson's disease. Neurology 1998;51(suppl 2):S25-S29.
27. Sato Y, Asoh T, Metoki N, Sato K. Efficacy of methylprednisolone pulse therapy on neuroleptic malignant syndrome in Parkinson's disease J Neurol Neurosurg Psychiatry 2003;74:574-576.
28. Thomas A, Iacono D, Luciano AL, Armellino K, Di Iorio A, Onofrj M. Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. J Neurol Neurosurg Psychiatry 2004;75:141-143.
29. McNaught KS, Jenner P. Extracellular accumulation of nitric oxide, hydrogen peroxide, and glutamate in astrocytic cultures following glutathione depletion, complex I inhibition, and/or lipopolysaccharide-induced activation. Biochem Pharmacol 2000;60:979-998.
30. Perry VH, Newman TA, Cunningham C. The impact of systemic infection on the progression of neurodegenerative disease. Nat Neurosci Rev 2003;4:103-112.
31. Dumartin B, Caille I, Gonon F, Bloch B. Internalization of D1 dopamine receptor in striatal neurons in vivo as evidence of activation by dopamine agonists. J Neurosci 1998;18:1650-1661.
32. Muriel MP, Bernard V, Levey AI, et al. Levodopa induces a cytoplasmic localization of D1 dopamine receptors in striatal neurons in Parkinson's disease. Ann Neurol 1999;46:103-111.
33. Agnati LF, Ferré S, Lluis C, Franco R, Fuxe K. Molecular mechanisms and therapeutical implications of intramembrane receptor/receptor interactions among heptahelical receptors with examples from the striatopallidal GABA neurons. Pharamacol Rev 2003;55:509-550.